Report cover image

U.S. Complex & Chronic Condition Management Market (By Disease Type: Cardiovascular Diseases, Oncology, Musculoskeletal, Women’s Health/Fertility/Maternity, Chronic Obstructive Pulmonary Disease, Others; By Service: Consulting Service, Implementation Se

Publisher Nova One Advisor
Published May 26, 2025
Length 655 Pages
SKU # ONEA20057920

Description

The U.S. complex & chronic condition management market size was estimated at USD 4.65 billion in 2023 and is projected to hit around USD 16.25 billion by 2033, growing at a CAGR of 13.33% during the forecast period from 2024 to 2033.

Key Takeaways:

By Services, the Implementation service segment has captured revenue share of around 42.98% in 2023.
By Services, the consulting services segment has accounted revenue share of around 34.63% in 2023.
By Disease Type, the cardiovascular diseases segment has held revenue share of 28.24% in 2023.
By Disease Type, the oncology segment has generated 25.10% revenue share in 2023.

U.S. Complex & Chronic Condition Management Market Overview
Due of lockdown constraints, the adoption of telemedicine and chronic condition management services in the United States increased dramatically during the epidemic. Furthermore, the possibility of contracting COVID-19 infections compelled many to stay at home. This situation encouraged the use of chronic condition management solutions by individuals suffering from one or more chronic diseases. Telehealth services enabled patients to take better care of their health and prevent harmful repercussions from delayed care.
Furthermore, the development of a robust telecommunications and information technology infrastructure aided the expansion of telemedicine and chronic care management. The majority of the population had access to cellphones and the internet, which accelerated the expansion of the complicated and chronic condition management industry in the United States. This trend is projected to continue during the forecast period, and the US & chronic condition market is expected to grow rapidly.
U.S. Complex & Chronic Condition Management Market Report Scope

Report Attribute

Details

Market Size in 2024
USD 5.27 Billion

Market Size by 2033
USD 16.25 Billion

Growth Rate From 2024 to 2033
CAGR of 13.33%

Base Year
2023

Forecast Period
2024 to 2033

Segments Covered
Service, Disease Type

Market Analysis (Terms Used)
Value (US$ Million/Billion) or (Volume/Units)

Report Coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Key Companies Profiled
AllScripts, Siemens Healthineers, Koninklijke Philips N.V., Pegasystems, Inc., Cognizant TriZetto Software Group Inc., IBM Corporation, ScienceSoft USA, MINES & Associates, Inc., Healthcare at Home, Mediware Information Systems

U.S. Complex & Chronic Condition Management Market Growth
Chronic condition refers to patients who have been suffering from an illness for many years, and the afflicted cells progress over time. Chronic diseases are the primary revenue generators for the healthcare business. Complex and chronic condition management is a program that assists patients and healthcare professionals in improving healthcare services and the patient's quality of life. Chronic condition management services serve patients from various medical services. The expansion of digital technologies has fueled the growth of the telehealth business. The increased adoption of telehealth services by healthcare professionals and consumers is the key driver of the US complicated and chronic condition management market.
Approximately half of the US population suffers from at least one chronic condition. The most common chronic diseases in the United States include cardiovascular disease, cancer, COPD, diabetes, and musculoskeletal problems. These chronic diseases are the leading causes of death in the United States. The rising prevalence of chronic diseases, combined with rising healthcare costs, is expected to drive demand for novel and sophisticated complicated and chronic condition management services.
The growing geriatric population is another important element influencing market growth. The geriatric population in the United States is steadily increasing. Furthermore, the elderly are more susceptible to chronic ailments and tend to spend more on their health. As a result, the growing senior population, combined with rising healthcare expenditure, is predicted to considerably drive market expansion throughout the forecast period.
U.S. Complex and Chronic Condition Management Market By Disease Type Insights
Cardiovascular diseases accounted for the largest market share at 28.24% in 2023, and this trend is expected to continue over the projected period. The increased prevalence of cardiovascular diseases in US is the primary contributor to the growth of the complex and chronic condition management market. The proliferation of the digital technologies and development of advanced software systems has enabled a systematic care delivery in the US healthcare sector, which helps the patients to avoid any exacerbations and complications. The complex and chronic condition management solution connects the patients devices like smartphones and tablets with the electronic health records (EHR) through an app installed in the patients’ device. This solutions analyses the cardiovascular health of the patient, processes the information, and provides alerts and notifications that helps in the timely diagnosis and treatment. The complex and chronic condition management solution and the mobile app serve as a crucial communication point between the caregiver and the patient.

Chronic Obstructive Pulmonary Disease (COPD) are expected to witness maximum gains over the forecast period due to rising patient preference for the complex and chronic condition management services for the COPD condition management. Moreover, the rising prevalence of the COPD among the US population is boosting the growth. It is estimated that around 14.8 million adults in US have been diagnosed with COPD in 2020.
U.S. Complex and Chronic Condition Management Market By Service Insights
The implementation services segment dominated the complex and chronic condition management market in US. The telehealth service providers play a crucial role in connecting the patients and the care providers. The arrangements are done by the service providers when a patient requires visiting a clinic or a hospital to acquire therapies and tests. The increased prevalence of various chronic diseases that frequently requires implementation services has fostered the growth of this segment. The patients suffering from the diseases such as cancer, reproductive disorder, and musculoskeletal disorders regularly needs the in-person care for receiving various therapies and conduct tests. Therefore, the implementation services have captured a huge market share owing to its higher revenue generation.
The education services are expected to be the fastest-growing segment. The education services are necessary for various patients who are suffering from COPD and different musculoskeletal conditions. The necessity for gaining information regarding the management of certain health conditions is driving the growth of the education services. The health education service providers are increasingly adopting the digital technologies for reaching out to the consumers. The education services play a major role in the self-management of chronic conditions.
U.S. Complex and Chronic Condition Management Market Key Developments

In 2020, Allscripts announced a definitive agreement to sell its CarePort Health business to WellSky Corp. CarePort solutions assist hundreds of hospitals and post-acute care providers to efficiently coordinate and transition patients through different settings of care.
In 2020, ScienceSoft received licenses in the United Arab Emirates to offer IT services, IT solutions and IT consultancy and opened its first Middle East office in the UAE. The Middle East launch solidifies ScienceSoft’s aspiration to tap into new markets and grow international presence.
Siemens Healthineers and KlinikumLippe GmbH (KLG) had entered into a ten-year technology partnership for all the healthcare provider’s locations. The contract covers delivery and maintenance of large imaging equipment and ultrasound units.

U.S. Complex & Chronic Condition Management Market Top Key Companies:

AllScripts
Siemens Healthineers
Koninklijke Philips N.V.
Pegasystems, Inc.
Cognizant TriZetto Software Group Inc.
IBM Corporation
ScienceSoft USA
MINES & Associates, Inc.
Healthcare at Home
Mediware Information Systems

U.S. Complex & Chronic Condition Management Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Complex & Chronic Condition Management market.
By Disease Type

Cardiovascular Diseases
Oncology
Musculoskeletal
Women’s Health/Fertility/Maternity
Chronic Obstructive Pulmonary Disease
Others

By Service

Consulting Service
Implementation Service
Education Service
Others

Table of Contents

655 Pages
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Complex & Chronic Condition Management Market
5.1. COVID-19 Landscape: Complex & Chronic Condition Management Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. U.S. Complex & Chronic Condition Management Market, By Disease
8.1. Complex & Chronic Condition Management Market, by Disease Type, 2021-2027
8.1.1. Cardiovascular Diseases
8.1.1.1. Market Revenue and Forecast (2017-2027)
8.1.2. Oncology
8.1.2.1. Market Revenue and Forecast (2017-2027)
8.1.3. Musculoskeletal
8.1.3.1. Market Revenue and Forecast (2017-2027)
8.1.4. Women’s Health/Fertility/Maternity
8.1.4.1. Market Revenue and Forecast (2017-2027)
8.1.5. Chronic Obstructive Pulmonary Disease
8.1.5.1. Market Revenue and Forecast (2017-2027)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017-2027)
Chapter 9. U.S. Complex & Chronic Condition Management Market, By Service
9.1. Complex & Chronic Condition Management Market, by Service, 2021-2027
9.1.1. Consulting Service
9.1.1.1. Market Revenue and Forecast (2017-2027)
9.1.2. Implementation Service
9.1.2.1. Market Revenue and Forecast (2017-2027)
9.1.3. Education Service
9.1.3.1. Market Revenue and Forecast (2017-2027)
9.1.3.2.
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2027)
Chapter 10. U.S. Complex & Chronic Condition Management Market, U.S. Estimates and Trend Forecast
10.1. U. S.
10.1.1. Market Revenue and Forecast, by Disease (2017-2027)
10.1.2. Market Revenue and Forecast, by Service (2017-2027)
Chapter 11. Company Profiles
11.1. AllScripts
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Siemens Healthineers
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Koninklijke Philips N.V.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Pegasystems, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Cognizant TriZetto Software Group Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. IBM Corporation
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. ScienceSoft USA
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. MINES & Associates, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Healthcare at Home
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Mediware Information Systems
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Breast Cancer Diagnostics Market
5.1. COVID-19 Landscape: Breast Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Breast Cancer Diagnostics Market, By Product
8.1. Breast Cancer Diagnostics Market, by Product Type, 2023-2032
8.1.1. Platform-based Products
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Instrument-based Products
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Breast Cancer Diagnostics Market, By Type
9.1. Breast Cancer Diagnostics Market, by Type, 2023-2032
9.1.1. Imaging
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Biopsy
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Genomic Tests
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Blood Tests
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Breast Cancer Diagnostics Market, By Application Type
10.1. Breast Cancer Diagnostics Market, by Application Type, 2023-2032
10.1.1. Screening
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Diagnostic and Predictive
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Prognostic
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Breast Cancer Diagnostics Market, By End Use Type
11.1. Breast Cancer Diagnostics Market, by End Use Type, 2023-2032
11.1.1. Hospitals & Clinics
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Diagnostic Centers & Medical Laboratories
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Breast Cancer Diagnostics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.2. Market Revenue and Forecast, by Type (2021-2033)
12.1.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.1.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Type (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.1.5.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Type (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.1.6.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.2. Market Revenue and Forecast, by Type (2021-2033)
12.2.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.2.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Type (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.2.5.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Type (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.2.6.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Type (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.2.7.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Type (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.2.8.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.2. Market Revenue and Forecast, by Type (2021-2033)
12.3.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.3.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Type (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.3.5.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Type (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.3.6.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Type (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.3.7.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Type (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.3.8.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.2. Market Revenue and Forecast, by Type (2021-2033)
12.4.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.4.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Type (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.4.5.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Type (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.4.6.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Type (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.4.7.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Type (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.4.8.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.2. Market Revenue and Forecast, by Type (2021-2033)
12.5.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.5.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Type (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.5.5.4. Market Revenue and Forecast, by End Use Type (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Type (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Application Type (2021-2033)
12.5.6.4. Market Revenue and Forecast, by End Use Type (2021-2033)
Chapter 13. Company Profiles
13.1. Genomic Health
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. NanoString Technologies Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Paragon Biosciences LLC
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Devicor Medical Products Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Quest Diagnostics Incorporated
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Koninklijke Philips N.V.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Siemens AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Biocept Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Epigenomics Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.